What changed today in Metabolic: 5 trial updates, 3 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records11 sources1 min read
Retatrutide
Retatrutide is a triple agonist of the GIP, GLP-1 and glucagon receptors developed by Eli Lilly. Its clinical-trial progress and regulatory status are tracked on this page from official sources.
Emerging
- Editorial attention
- Emerging
- Tracked this week
- 2
- Sources this week
- 2
- Last activity
- Nov 8, 2026
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Retatrutide at a glance
- About this topic
- Retatrutide is a triple agonist of the GIP, GLP-1 and glucagon receptors developed by Eli Lilly. Its clinical-trial progress and regulatory status are tracked on this page from official sources.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: Results posted on ClinicalTrials.gov: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2… (opens the source in a new tab) (ClinicalTrials.gov (U.S. National Library of Medicine), Nov 8, 2026)
- Key facts from tracked records
- 20 clinical trials tracked from ClinicalTrials.gov
- 3 NPHLA briefings on this topic
What’s the latest on Retatrutide?
3 totalWhat changed today in Metabolic: 4 trial updates, 3 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records10 sources1 min read
Clinical trial phases, explained: what phase 1, 2, 3 and 4 tell you
Phase labels appear in every drug-pipeline headline. Here is what each phase is designed to answer, how large the studies typically are, and what a phase label does not tell you.
AI-assisted · Editor reviewed2 sources2 min read
What do the official records show?
Primary sources and peer-reviewed research- Results posted on ClinicalTrials.gov: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2… (opens the source in a new tab)
Phase 2, Eli Lilly and Company. Conditions: Overweight or Obesity; CKD; Type 2 Diabetes. Interventions: Retatrutide; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
- Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (opens the source in a new tab)
- Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis (opens the source in a new tab)
- Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial (opens the source in a new tab)
Which clinical trials are being tracked?
All trials- Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Eli Lilly and Company. Conditions: Type 2 Diabetes. Investigational — not approved for the use studied.
- GZBF: Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight
Hudson Biotech. Conditions: Obesity. Investigational — not approved for the use studied.
- TRIUMPH-8: A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
Eli Lilly and Company. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Eli Lilly and Company. Conditions: Overweight or Obesity; CKD; Type 2 Diabetes. Results posted 2026-11-09. Investigational — not approved for the use studied.
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly and Company. Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease. Investigational — not approved for the use studied.
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company. Conditions: Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD). Investigational — not approved for the use studied.